Rheumatology Drug Updates: Sirukumab Promising for RA, Plus Efficacy Duration of Ustekinumab for Plaque Psoriasis

Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

Aletaha D, Bingham CO, Tanaka Y, et al. Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): A randomized, double-blind, placebo-controlled, parallel-group, multi-national, Phase 3 study. The Lancet. 2017 Feb 15. pii: S0140–6736(17)30401-4. doi: 10.1016/S0140-6736(17)30401-4. [Epub ahead of print]
Janssen Pharmaceutical Co. of Johnson & Johnson. News release: Janssen submits application seeking approval of sirukumab in United States for rheumatoid arthritis. 2016 Sep 23.
GlaxoSmithKline plc. GSK pipeline Phase III: Sirukumab. 2017.
Shalom G, Cohen AD, Ziv M et al. Biologic drug survival in Israeli psoriasis patients. J Am Acad Dermatol. 2016 Dec 28. pii:S0190–9622(16)31008-8. doi: 10.1016/j.jaad.2016.10.033. [Epub ahead of print]

In a clinical trial, RA patients on sirukumab experienced decreased disease activity and improved physical function…

Citing safety concerns, the FDA Arthritis Advisory Committee voted against recommending approval of sirukumab for treating adults with RA…

Abatacept Approved for Adult PsA On June 30, the U.S. Food and Drug Administration (FDA) approved abatacept (Orencia) to treat adults with active psoriatic arthritis (PsA).1 Abatacept is available as both an intravenous formulation and a subcutaneous injection.2 The approval was based on results of two randomized, double-blind, placebo-controlled trials, PsA-I and PsA-II, during which…

Three clinical trials are evaluating subcutaneous sirukumab for safety and efficacy in treating rheumatoid arthritis. And a study found no significant difference in persistence and remission for TNF-α monotherapy when compared with TNF-α plus conventional DMARD combination therapy for treating psoriatic arthritis…

References

Sirukumab Promising for RA

Sirukumab Approval Stalls

Abatacept Approved for Psoriatic Arthritis in Adults; Sirukumab Approval Stalls

3 Clinical Trials Examine Sirukumab for RA; Plus TNF-α Combination & Monotherapies Are Compared for Treating PsA

References

Related Articles